Carl Icahn’s Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund increased its stakes in two holdings, ...

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $136.00. The ...

Shares of Illumina Inc. ILMN shed 1.51% to $100.24 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...

Shares of Illumina Inc. ILMN shed 5.47% to $104.99 Monday, on what proved to be an all-around favorable trading session for ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 49.02% Upside As of January ...

A number of other analysts also recently weighed in on the company. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Dissects President Trump’s China Tariffs. In this ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...